Floatz logo

FTC-146

Spinal Pain

Stanford UniversitySmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Spinal Pain cohort.

Asset / SponsorPhaseRating
Oxycodone
Grünenthal GmbH
Phase 4BBB
DINITROGEN MONOXIDE
Medical College of Wisconsin
Phase 4BB
LIDOCAINE
Medical College of Wisconsin
Phase 4BB
Bxcl501
Medical College of Wisconsin
Phase 4BB
NEPENTHE
MedtronicNeuro
Phase 4BB

View all 41 →

Same molecule, other indications

FTC-146 is also rated in:

Pediatric DisorderDormant
CC
Indicative ·
47 / 100
View asset →
Nociceptive PainDormant
CC
Indicative ·
47 / 100
View asset →
neuralgiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →